Literature DB >> 1411764

Prevalence of scoliosis in children with myelomeningocele in western Sweden.

E B Müller1, A Nordwall.   

Abstract

In a cross-sectional study of the prevalence of scoliosis in patients with myelomeningocele, 131 patients 5-20 years of age were investigated with clinical examination and radiograms. Sixty-nine percent of the myelomeningocele patients had scoliosis, this prevalence being present already at a young age (6 years). The occurrence of scoliosis increased drastically at high levels of dysraphism, being 20% in patients with sacral myelomeningocele but 94% in patients with thoracic MMC level. Between ages 5 and 10, the mean scoliosis increased successively from 15 to 33 degrees. After this age there was no significant further increase. The ambulatory status of the patients was strongly correlated to the scoliosis incidence. Forty-nine percent of the patients had a uni- or bilateral hip dislocation. There was no correlation between the side of the scoliosis convexity and the side of hip dislocation.

Entities:  

Mesh:

Year:  1992        PMID: 1411764     DOI: 10.1097/00007632-199209000-00015

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  3 in total

1.  Correlation of spine deformity, lung function, and seat pressure in spina bifida.

Authors:  Jayesh Patel; Janet L Walker; Vishwas R Talwalkar; Henry J Iwinski; Todd A Milbrandt
Journal:  Clin Orthop Relat Res       Date:  2011-05       Impact factor: 4.176

2.  What is the Role of Scoliosis Surgery in Adolescents and Adults with Myelomeningocele? A Systematic Review.

Authors:  Viachaslau Bradko; Heidi Castillo; Ellen Fremion; Michael Conklin; Benny Dahl; Jonathan Castillo
Journal:  Clin Orthop Relat Res       Date:  2022-04-01       Impact factor: 4.755

3.  Response of Scoliosis in Children with Myelomeningocele to Surgical Release of Tethered Spinal Cord.

Authors:  Haluk Altiok; Anne Riordan; Adam Graf; Joe Krzak; Sahar Hassani
Journal:  Top Spinal Cord Inj Rehabil       Date:  2016
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.